Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Teladoc, a pure-play telehealth company, should see another weak performance in 2026. The company's revenue growth has been slow (at best), even without recent Medicare-related changes.

Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its 2024 Physician Compensation Report. The report reveals that ...

Doximity Inc’s stock recently reached a 52-week low, trading at $38.75, just pennies above its 52-week bottom of $38.90. This milestone underscores a challenging year for the co ...

Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report ...

AI-powered medical search platform OpenEvidence Inc. can move forward with most of its lawsuit alleging rival Doximity Inc.

Shares of medical professional network Doximity (NYSE:DOCS) fell 3.2% in the afternoon session after Goldman Sachs downgraded the stock to Sell from a Neutral rating. The investment bank cited ...

Doximity is up 6.9% since the beginning of the year, but at $46.28 per share, it is still trading 44.3% below its 52-week ...

Doximity just posted stellar quarterly results, driven by stable advertising demand. This helped the company achieve sky-high profitability, which could help it remain critical to advertisers.

While Doximity CEO Jeff Tangney believes we are still in the “early innings” of the digital healthcare advertising revolution, his social networking company for doctors scored a home run on its first ...